Richard D. Drake

Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

Amanda N. Fader, Richard D. Drake, David M. O’Malley et al. · Cancer · 2009 · 165 citations

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

John O. Schorge, Richard D. Drake, Hang Lee et al. · Clinical Cancer Research · 2004 · 108 citations · Full text

Ovarian Preservation in Stage I Low-Grade Endometrial Stromal Sarcomas

Andrew J. Li, Robert Giuntoli, Richard D. Drake et al. · Obstetrics and Gynecology · 2005 · 102 citations

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

Don S. Dizon, John A. Blessing, Richard T. Penson et al. · Gynecologic Oncology · 2012 · 96 citations

Phase Ii Evaluation, Medicine, Persistent Platinum-resistant Ovarian +8

Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes

Amanda N. Fader, Christa Nagel, Allison E. Axtell et al. · Gynecologic Oncology · 2009 · 84 citations

Survival Outcomes, Medicine, Cancer Management +7